Currently, there are 41.10M common shares owned by the public and among those 37.95M shares have been available to trade.
The company’s stock has a 5-day price change of 19.82% and 36.00% over the past three months. ACHL shares are trading 19.30% year to date (YTD), with the 12-month market performance up to 36.00% higher. It has a 12-month low price of $0.63 and touched a high of $1.76 over the same period. ACHL has an average intraday trading volume of 175.74K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 17.05%, 23.61%, and 46.16% respectively.
Institutional ownership of Achilles Therapeutics Plc ADR (NASDAQ: ACHL) shares accounts for 51.53% of the company’s 41.10M shares outstanding.
It has a market capitalization of $55.90M and a beta (3y monthly) value of 1.31. The earnings-per-share (ttm) stands at -$1.66. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.48% over the week and 3.59% over the month.
Earnings per share for the fiscal year are expected to increase by 89.66%, and 33.33% over the next financial year.
Looking at the support for the ACHL, a number of firms have released research notes about the stock. Piper Sandler stated their Neutral rating for the stock in a research note on April 05, 2024, with the firm’s price target at $8-$2. Piper Sandler coverage for the Achilles Therapeutics Plc ADR (ACHL) stock in a research note released on April 26, 2021 offered a Overweight rating with a price target of $25. Oppenheimer was of a view on April 26, 2021 that the stock is Outperform, while JP Morgan gave the stock Underweight rating on April 26, 2021, issuing a price target of $11. Chardan Capital Markets on their part issued Buy rating on April 26, 2021.
